Raymond James Archives - Page 2 of 4

Developments

Raymond James sees high likelihood of CPT-1 reimbursement for Profound’s TULSA-PRO

Analyst Rahul Sarugaser, Ph.D., writes that there is a high likelihood that Profound Medical (NASDAQ:PROF) will receive a category-1 CPT code from the Centers for Medicare and Medical Services when it files an...

November 15, 2022

Markets

Raymond James cuts Cardiol Therapeutics to MP; PT to $4 (Canadian)

Raymond James downgraded Cardiol Therapeutics (TSX:CRDL) to “market perform” from “outperform” and trimmed its price target to $4 (Canadian) from $5, citing a slower than expected enrollment in Cardiol’s LANCER clinical...

March 16, 2022

Markets

Raymond James starts Medexus at OP; PT $5.50 (Canadian)

Raymond James initiated coverage of Medexus Pharmaceuticals (TSX:MDP) with an “outperform” rating and price target of $5.50 (Canadian). The stock closed at $3.32 on Feb. 18. Medexus is a fully integrated, specialty...

February 22, 2022

Markets

Raymond James ups Opsens to strong buy; PT $6 (Canadian)

Raymond James upgraded Opsens (TSX:OPS) to “strong buy” from “outperform” with a price target of $6 (Canadian) after the company said its TAVR trial was “very successful.” The stock was quoted at $2.99, down 40 cents...

November 23, 2021

Markets

Raymond James ups Alpha Cognition PT to $3.50 (Canadian)

Raymond James raised its price target for Alpha Cognition (TSXV:ACOG) to $3.50 (Canadian) from $2.50 and maintained its “outperform” rating after the FDA accepted Alpha’s IND application to proceed into a pivotal...

September 7, 2021

Developments

Raymond James study finds superior safety and TAM with Profound Medical’s TULSA-PRO

Raymond James gave winning marks to Profound Medical‘s (NASDAQ:PROF; TSX:PRN) TULSA-PRO device, compared with the Focal One HIFU device from France’s EDAP TMS SA (NASDAQ:EDAP), in a head-to-head comparison study...

August 26, 2021

Markets

Raymond James ups HLS Therapeutics to OP; PT to $26 (Canadian)

Raymond James upgraded HLS Therapeutics (TSX:HLS) to “outperform” from “market perform” and raised its price target to $26 (Canadian) from $24 after Pfizer agreed to co-market HLS’s cardiovascular drug...

August 16, 2021

Markets

Raymond James starts Alpha Cognition at OP; PT $2.50 (Canadian)

Raymond James initiated coverage of Alpha Cognition (TSXV:ACOG) with an “outperform” rating and price target of $2.50 (Canadian). The stock closed at 80 cents on June 2. Alpha is in the late stages of clinical...

June 3, 2021

Markets

Raymond James ups Cardiol Therapeutics to OP from MP

Raymond James upgraded Cardiol Therapeutics (TSX:CRDL) to “outperform” from “market perform,” citing enrollment of the first patient in a Phase 2/3 clinical trial investigating the cardioprotective properties of...

April 28, 2021

Markets

Raymond James ups Perimeter Medical Imaging PT to $6.50 (Canadian) from $3

Raymond James raised its price target for Perimeter Medical Imaging (TSXV:PINK) to $6.50 (Canadian) from $3, citing a deeper look at the artificial intelligence-enabled application of the company’s Optical...

April 5, 2021

Tag - Raymond James

Raymond James sees high likelihood of CPT-1 reimbursement for Profound’s TULSA-PRO

Raymond James cuts Cardiol Therapeutics to MP; PT to $4 (Canadian)

Raymond James starts Medexus at OP; PT $5.50 (Canadian)

Raymond James ups Opsens to strong buy; PT $6 (Canadian)

Raymond James ups Alpha Cognition PT to $3.50 (Canadian)

Raymond James study finds superior safety and TAM with Profound Medical’s TULSA-PRO

Raymond James ups HLS Therapeutics to OP; PT to $26 (Canadian)

Raymond James starts Alpha Cognition at OP; PT $2.50 (Canadian)

Raymond James ups Cardiol Therapeutics to OP from MP

Raymond James ups Perimeter Medical Imaging PT to $6.50 (Canadian) from $3

General

More